全文获取类型
收费全文 | 1402256篇 |
免费 | 100040篇 |
国内免费 | 7829篇 |
专业分类
耳鼻咽喉 | 20100篇 |
儿科学 | 40925篇 |
妇产科学 | 39489篇 |
基础医学 | 195335篇 |
口腔科学 | 40925篇 |
临床医学 | 121619篇 |
内科学 | 272345篇 |
皮肤病学 | 30910篇 |
神经病学 | 109764篇 |
特种医学 | 55983篇 |
外国民族医学 | 476篇 |
外科学 | 214899篇 |
综合类 | 42746篇 |
现状与发展 | 23篇 |
一般理论 | 438篇 |
预防医学 | 96116篇 |
眼科学 | 33133篇 |
药学 | 107111篇 |
78篇 | |
中国医学 | 6619篇 |
肿瘤学 | 81091篇 |
出版年
2018年 | 14040篇 |
2017年 | 11564篇 |
2016年 | 12549篇 |
2015年 | 14914篇 |
2014年 | 20507篇 |
2013年 | 28363篇 |
2012年 | 37593篇 |
2011年 | 40325篇 |
2010年 | 23918篇 |
2009年 | 22601篇 |
2008年 | 36860篇 |
2007年 | 40026篇 |
2006年 | 40720篇 |
2005年 | 39371篇 |
2004年 | 37219篇 |
2003年 | 36168篇 |
2002年 | 35340篇 |
2001年 | 65052篇 |
2000年 | 66850篇 |
1999年 | 57164篇 |
1998年 | 15838篇 |
1997年 | 14739篇 |
1996年 | 13913篇 |
1995年 | 13086篇 |
1994年 | 12217篇 |
1992年 | 43307篇 |
1991年 | 41747篇 |
1990年 | 40963篇 |
1989年 | 39888篇 |
1988年 | 37246篇 |
1987年 | 36643篇 |
1986年 | 35112篇 |
1985年 | 33242篇 |
1984年 | 24904篇 |
1983年 | 21115篇 |
1982年 | 12687篇 |
1981年 | 11613篇 |
1979年 | 23956篇 |
1978年 | 17068篇 |
1977年 | 14834篇 |
1976年 | 13386篇 |
1975年 | 15267篇 |
1974年 | 18080篇 |
1973年 | 17560篇 |
1972年 | 16810篇 |
1971年 | 15717篇 |
1970年 | 14914篇 |
1969年 | 14346篇 |
1968年 | 13460篇 |
1967年 | 12015篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
41.
42.
43.
44.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献
45.
Harit Kapoor Kush Raj Lohani Tommy H. Lee Devendra K. Agrawal Sumeet K. Mittal 《CTS Clinical and Translational Science》2015,8(6):841-847
Esophageal adenocarcinoma is the fastest rising cancer in the United States. It develops from long‐standing gastroesophageal reflux disease which affects >20% of the general population. It carries a very poor prognosis with 5‐year survival <20%. The disease is known to sequentially progress from reflux esophagitis to a metaplastic precursor, Barrett''s esophagus and then onto dysplasia and esophageal adenocarcinoma. However, only few patients with reflux develop Barrett''s esophagus and only a minority of these turn malignant. The reason for this heterogeneity in clinical progression is unknown. To improve patient management, molecular changes which facilitate disease progression must be identified. Animal models can provide a comprehensive functional and anatomic platform for such a study. Rats and mice have been the most widely studied but disease homology with humans has been questioned. No animal model naturally simulates the inflammation to adenocarcinoma progression as in humans, with all models requiring surgical bypass or destruction of existing antireflux mechanisms. Valuable properties of individual models could be utilized to holistically evaluate disease progression. In this review paper, we critically examined the current animal models of Barrett''s esophagus, their differences and homologies with human disease and how they have shaped our current understanding of Barrett''s carcinogenesis. 相似文献
46.
47.
48.
49.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention
下载免费PDF全文
![点击此处可从《Journal of advanced nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
50.
Platelet function has been described by many laboratory assays, and PL-11 is a new point-of-care platelet function analyzer based on platelet count drop method, which counts platelet before and after the addition of agonists in the citrated whole blood samples. The present study sought to compare PL-11 with other three major more established assays, light transmission aggregometry (LTA), VerifyNow? aspirin system and thromboelastography (TEG), for monitoring the short-term aspirin responses in healthy individuals. Ten healthy young men took 100?mg/d aspirin for 3-day treatment. Platelet function was measured via PL-11, LTA, VerifyNow and TEG, respectively. The blood samples were collected at baseline, 2 hour, 1 day during the aspirin treatment and 1 day, 5?±?1 days, 8?±?1 days after the aspirin withdrawal. Moreover, 90 additional healthy subjects were recruited to establish a reference range for PL-11. Platelet function of healthy subjects decreased significantly 2 hours after 100?mg/d aspirin intake and began to recover during 4–6 days after the aspirin withdrawal. Correlations between methods were PL-11 vs. LTA (r?=?0.614, p?<?0.01); PL-11 vs. VerifyNow (r?=?0.829, p?<?0.01); PL-11 vs. TEG (r?=?0.697, p?<?0.001). There was no significant bias between PL-11 and LTA at baseline (bias?=?1.94%, p?=?0.804) using Bland-Altman analysis, while the data of PL-11 were significantly higher than LTA (bias?=?24.02%, p?<?0.001) during the aspirin therapy. The reference range for PL-11 in healthy young individuals was from 66.8 to 90.5% (95%CI). When aspirin low-responsiveness was defined as LTA?>?20%, the cut-off values for each method were, respectively: PL-11?>?50%, VerifyNow?>?533 ARU, TEG?>?60.2%. The results of different platelet function assays were uninterchangeable for monitoring aspirin response and correlations among them were also varied. Correlations among PL-11 and other three major assays suggested the ability of PL-11 to assess the treatment effects of aspirin. But a large cohort study is needed to confirm the cut-off value of aspirin response detected by PL-11. 相似文献